KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$202.4 million.

  • Novavax's Consolidated Net Income fell 6684.17% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 21997.03%. This contributed to the annual value of -$187.5 million for FY2024, which is 6560.04% up from last year.
  • Latest data reveals that Novavax reported Consolidated Net Income of -$202.4 million as of Q3 2025, which was down 6684.17% from $106.5 million recorded in Q2 2025.
  • Novavax's Consolidated Net Income's 5-year high stood at $518.6 million during Q1 2025, with a 5-year trough of -$846.3 million in Q4 2021.
  • Moreover, its 5-year median value for Consolidated Net Income was -$168.6 million (2022), whereas its average is -$142.7 million.
  • As far as peak fluctuations go, Novavax's Consolidated Net Income plummeted by 191082.7% in 2021, and later soared by 45150.53% in 2025.
  • Novavax's Consolidated Net Income (Quarter) stood at -$846.3 million in 2021, then skyrocketed by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then surged by 54.58% to -$81.0 million in 2024, then plummeted by 149.76% to -$202.4 million in 2025.
  • Its Consolidated Net Income stands at -$202.4 million for Q3 2025, versus $106.5 million for Q2 2025 and $518.6 million for Q1 2025.